Marshall Financial Group LLC Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Marshall Financial Group LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,581 shares of the company’s stock, valued at approximately $857,000.

Several other large investors have also recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans increased its stake in shares of Medpace by 44.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 8,946 shares of the company’s stock valued at $3,685,000 after acquiring an additional 2,741 shares during the last quarter. Evergreen Capital Management LLC acquired a new position in Medpace during the second quarter worth approximately $216,000. Fred Alger Management LLC purchased a new position in Medpace during the second quarter worth approximately $1,690,000. AXA S.A. boosted its holdings in shares of Medpace by 11.4% in the 2nd quarter. AXA S.A. now owns 34,018 shares of the company’s stock valued at $14,010,000 after purchasing an additional 3,479 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Medpace by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company’s stock valued at $8,702,000 after buying an additional 94 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Trading Down 1.1 %

NASDAQ MEDP opened at $344.07 on Friday. The stock has a market cap of $10.69 billion, a P/E ratio of 30.13, a PEG ratio of 1.77 and a beta of 1.36. The company’s fifty day simple moving average is $340.33 and its 200-day simple moving average is $355.57. Medpace Holdings, Inc. has a 52 week low of $286.76 and a 52 week high of $459.77.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MEDP shares. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Truist Financial cut their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Robert W. Baird raised their price target on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday, November 25th. Finally, Redburn Atlantic started coverage on shares of Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price target on the stock. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.